| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 The Burnham Institute, La Jolla, CA, USA. 2 Institute of Pediatric Clinic, University of Rome La Sapienza, and 3 Dept of Biopathology and Imaging Diagnostics, Division of Medical Statistics, University of Rome Tor Vergata, Rome, Italy
To the Editor:
In a cohort of asthmatic children, we have recently shown that the ABO-secretor genetic complex influences susceptibility to asthma in children 1.
Since previous studies have shown an association of asthma with adenosine deaminase (ADA) genotype 2, we have searched for possible interactions between the two systems concerning their effects on susceptibility to asthma in children.
The sample study has been described in a previous paper 1 and was composed of 165 children, 109 males and 56 females, aged from 1 month–15 yrs. The criterion for inclusion in the study was the occurrence of two or more episodes of wheezing in the last 6 months, irrespective of aetiology/pathogenesis of the attack.
A consecutive series of 362 newborn infants from the same Caucasian population in Rome, Italy, was used as the control sample.
ADA phenotype was determined by starch gel electrophoresis according to the method of Spencer et al. 3. ABO and secretor phenotypes were determined according to a standard laboratory procedure 1.
Table 1
shows the distribution of secretor-ABO-ADA joint genotype in asthmatic children and in the control population.
|
The lack of three-way interaction among secretor/ABO complex, ADA and disease (table 2), suggests that ADA does not influence the effect of the secretor-ABO complex and vice versa, thus indicating that there was not an epistatic effect. On the contrary, the analysis suggests a cooperative effect of the genetic factors on susceptibility to asthma.
|
) indicated that most of the difference between asthmatics and controls was due to the difference in the proportion of phenotypic categories nonsecretor/O with ADA*1/*1 phenotype (highest susceptibility to asthma) and other phenotypes of the secretor-ABO complex carrying the ADA*2 allele (lowest susceptibility to asthma). The odds ratio between these phenotypic categories was equal to 2.97.
|
In purine metabolism, the classical function of the ADA enzyme is considered to be the regulation of intra- and extracellular levels of adenosine. Recently, it has been demonstrated that ADA is present on the surface of many cell types, including lymphocytes and neurons, where it can act as an ectoenzyme 5. A costimulatory role has been observed for ADA bound with CD26 on the lymphocyte surface, while ADA bound with adenosine 1 receptors (A1R) on the neuronal surface seems to act as a direct local modulator of adenosine action on A1R, and also as a cell adhesion molecule thus having a role in neural development and plasticity processes 5.
Since the ADA*2 allele is associated with lower ADA enzymatic activity, the negative association of the ADA*2 carrier genotype with the disease could indicate a role of decreased local and/or systemic adenosine levels in the pathogenesis of asthma. The suppressive effects of adenosine on lymphocyte function suggests that the ADA*2 allele could, in part, protect against higher immune reactivity.
Four adenosine receptors (A1, A2a, A2b and A3) have been discovered on the surface of many different cell types 6. In the respiratory system, the bronchoconstrictor effects of adenosine are well known 7. Thus, ADA polymorphism could modulate adenosine receptor activity in the respiratory tract with effects on the signal transduction pathway of adenosine and other mediators.
Based on the different roles of the ABO-secretor complex and ADA in the functional integrity of the respiratory tract, it is likely that the effects of the two systems on susceptibility to asthma follow different pathways: the ABO-secretor complex acting on the bacterial-viral infective component and ADA on the cellular reactivity component. Thus, a priori, an epistatic interaction was unlikely and our analysis has confirmed the expectation.
At present the genetic analysis of multifactorial disorders is a central problem in medical genetics and there is a general consensus on the necessity of a nonreductionist approach 8. The analysis of single genetic factors, based on a mendelian perspective, cannot solve the problem. It would be more productive to define a set of genes functionally related to the disease and to study simultaneously genetic and environmental factors involved in the susceptibility to the disease. A comprehensive approach will help to evaluate gene-to-gene and gene-to-environment interactions and will help in the understanding of pathogenic mechanisms.
References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
